Protein 'switches' could turn cancer cells into tiny chemotherapy factories

September 23, 2011 in Cancer

Johns Hopkins researchers have devised a protein "switch" that instructs cancer cells to produce their own anti-cancer medication.

In lab tests, the researchers showed that these switches, working from inside the cells, can activate a powerful cell-killing drug when the device detects a marker linked to cancer. The goal, the scientists said, is to deploy a new type of weapon that causes cancer cells to self-destruct while sparing healthy tissue.

This new cancer-fighting strategy and promising early lab test results were reported this week in the online early edition of . Although the switches have not yet been tested on human patients, and much more testing must be done, the researchers say they have taken a positive first step toward adding a novel weapon to the difficult task of treating cancer.

One key problem in fighting cancer is that broadly applied chemotherapy usually also harms healthy cells. In the protein switch strategy, however, a doctor would instead administer a "prodrug," meaning an inactive form of a cancer-fighting drug. Only when a is present would the cellular switch turn this harmless prodrug into a potent form of chemotherapy.

"The switch in effect turns the cancer cell into a factory for producing the anti-cancer drug inside the cancer cell," said Marc Ostermeier, a Johns Hopkins chemical and biomolecular engineering professor in the Whiting School of Engineering, who supervised development of the switch.

"The healthy cells will also receive the prodrug," he added, "and ideally it will remain in its non-toxic form. Our hope is that this strategy will kill more cancer cells while decreasing the unfortunate side effects on healthy cells."

To demonstrate that these switches can work, the research team successfully tested them on human and in Ostermeier's lab and in the laboratory of James R. Eshleman, a professor of pathology and oncology in the Johns Hopkins School of Medicine.

"This is a radically different tool to attack cancers," said Eshleman, a co-author of the PNAS journal article, "but many experiments need to be done before we will be able to use it in patients."

The next step is animal testing, expected to begin within a year, Ostermeier said.

Ostermeier's team made the cancer-fighting switch by fusing together two different proteins. One protein detects a marker that cancer cells produce. The other protein, from yeast, can turn an inactive prodrug into a cancer-cell killer. "When the first part of the switch detects cancer, it tells its partner to activate the chemotherapy drug, destroying the cell," Ostermeier said.

In order for this switch to work, it must first get inside the cancer cells. Ostermeier said this can be done through a technique in which the switch gene is delivered inside the cell. The switch gene serves as the blueprint from which the cell's own machinery constructs the protein switch. Another approach, he said, would be to develop methods to deliver the switch protein itself to cells.

Once the switches are in place, the patient would receive the inactive chemotherapy drug, which would turn into a cancer attacker inside the cells where the switch has been flipped on.

Although many researchers are developing methods to deliver anti-cancer drugs specifically to cancer cells, Ostermeier said the protein switch tactic skirts difficulties encountered in those methods.

"The protein concept changes the game by providing a mechanism to target production of the anti-cancer drugs inside cancer cells instead of targeting delivery of the anti-cancer drug to ," he said.

More information: The paper, "A protein therapeutic modality founded on molecular recognition," can be viewed online at: http://www.pnas.or … ull.pdf+html

Provided by Johns Hopkins University search and more info website

4.5 /5 (8 votes)  

Rank 4.5 /5 (8 votes)
Relevant PhysicsForums posts
  • Potential Breakthrough in Seizure Control
    created4 hours ago
  • Popping/Cracked sternum.
    created9 hours ago
  • Which Mental Illness Encompasses This Problem?
    created9 hours ago
  • A question about drug tolerance
    createdMay 23, 2012
  • Poor nutrition leading to overeating?
    createdMay 23, 2012
  • Math and dyslexia?
    createdMay 21, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Skp2 activates cancer-promoting, glucose-processing Akt

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

Cancer created 17 hours ago | popularity not rated yet | comments 0 | with audio podcast

Pancreatectomy OK without downstaging from therapy

(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published ...

Cancer created 18 hours ago | popularity not rated yet | comments 0

Common therapies for basal cell carcinoma offer similar survival

(HealthDay) -- For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published ...

Cancer created 19 hours ago | popularity not rated yet | comments 0

Cancer may require simpler genetic mutations than previously thought

Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...

Cancer created 21 hours ago | popularity not rated yet | comments 0 | with audio podcast

New prostate cancer screening guidelines face a tough sell, study suggests

(Medical Xpress) -- Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter ...

Cancer created May 25, 2012 | popularity not rated yet | comments 1


Travel to high altitudes tied to Crohn's, colitis flare-ups

(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...

Transvaginal mesh op restores pelvic organ prolapse at price

(HealthDay) -- Transvaginal mesh (TVM) procedures are effective for anatomical restoration of pelvic organ prolapse (POP), but patients report a worsening of sexual function following surgery, according to ...

Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse

(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...

Inherited DNA change explains overactive leukemia gene

A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.

Tongue analysis software uses ancient Chinese medicine to warn of disease

For 5,000 years, the Chinese have used a system of medicine based on the flow and balance of positive and negative energies in the body. In this system, the appearance of the tongue is one of the measures used to classify ...

Early physical therapist treatment associated with reduced risk of healthcare utilization and reduced overall healthcare

A new study published in Spine shows that early treatment by a physical therapist for low back pain (LBP), as compared to delayed treatment, was associated with reduced risk of subsequent healthcare utilization and lower ...